These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7200365)

  • 1. Diurnal variation in biliary lipids and serum VLDL before and during treatment with cloribrate.
    Andersén E; Hellström K
    Atherosclerosis; 1982 Jan; 41(1):87-97. PubMed ID: 7200365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers.
    Oster P; Schlierf G; Lang PD; Mordasini R; Vollmar J
    Pharmatherapeutica; 1985; 4(5):267-77. PubMed ID: 4070320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man.
    Pertsemlidis D; Panveliwalla D; Ahrens EH
    Gastroenterology; 1974 Apr; 66(4):565-73. PubMed ID: 4821079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of clofibrate on lipoprotein-lipids in patients with type IV hyperlipoproteinaemia (author's transl)].
    Weisweiler P; Schwandt P
    Klin Wochenschr; 1977 Aug; 55(16):791-4. PubMed ID: 198601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of polyunsaturated fats on lipid metabolism in patients with hypertriglyceridemia.
    Grundy SM
    J Clin Invest; 1975 Feb; 55(2):269-82. PubMed ID: 233943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diurnal changes and adaptation by the liver of hamsters to an atherogenic diet.
    Robins SJ; Fasulo JM; Pritzker CR; Ordovas JM; Patton GM
    Am J Physiol; 1995 Dec; 269(6 Pt 2):R1327-32. PubMed ID: 8594933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.
    Naruszewicz M; Szostak WB; Cybulska C; Kozłowska M; Chotkowska E
    Atherosclerosis; 1980 Apr; 35(4):383-92. PubMed ID: 7378119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian variation of postprandial lipemia.
    Romon M; Le Fur C; Lebel P; Edmé JL; Fruchart JC; Dallongeville J
    Am J Clin Nutr; 1997 Apr; 65(4):934-40. PubMed ID: 9094875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1981 Jun; 11(3):185-9. PubMed ID: 6791937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma protein concentrations in hypertriglyceridaemic subjects. Effect of clofibrate and comparison with normal subjects.
    Ballantyne FC; Morrison BA; Ballantyne D; Dryburgh FJ; Epenetos AA
    Clin Chim Acta; 1978 Jul; 87(1):43-7. PubMed ID: 668144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of clofibrate and a fat-modified diet on serum lipids.
    Brown HB; Lewis LA; Page IH
    Clin Pharmacol Ther; 1975 Feb; 17(2):171-8. PubMed ID: 164312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus.
    Abrams JJ; Ginsberg H; Grundy SM
    Diabetes; 1982 Oct; 31(10):903-10. PubMed ID: 6759223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile acid kinetics, steroid balance and biliary lipids in hyperlipoproteinaemia type III.
    Andersén E; Hellström K; Vessby B
    Atherosclerosis; 1981 May; 39(2):191-201. PubMed ID: 7247999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diurnal lipid and lipoprotein profiles in hypertriglyceridemic patients with bezafibrate and clofibrate.
    Oster P; Lang PD; Vollmar J; Schlierf G
    Res Exp Med (Berl); 1986; 186(6):435-41. PubMed ID: 3823619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipoprotein lipids after gemfibrozil treatment.
    Schwandt P; Weisweiler P; Neureuther G
    Artery; 1979 Feb; 5(2):117-24. PubMed ID: 231950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diurnal variation of LDL and HDL cholesterol.
    Miettinen TA
    Ann Clin Res; 1980 Dec; 12(6):295-8. PubMed ID: 7195181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.